Cargando…
Immune oncology, immune responsiveness and the theory of everything
Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvi...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989400/ https://www.ncbi.nlm.nih.gov/pubmed/29871670 http://dx.doi.org/10.1186/s40425-018-0355-5 |
_version_ | 1783329454511095808 |
---|---|
author | Turan, Tolga Kannan, Deepti Patel, Maulik Matthew Barnes, J. Tanlimco, Sonia G. Lu, Rongze Halliwill, Kyle Kongpachith, Sarah Kline, Douglas E. Hendrickx, Wouter Cesano, Alessandra Butterfield, Lisa H. Kaufman, Howard L. Hudson, Thomas J. Bedognetti, Davide Marincola, Francesco Samayoa, Josue |
author_facet | Turan, Tolga Kannan, Deepti Patel, Maulik Matthew Barnes, J. Tanlimco, Sonia G. Lu, Rongze Halliwill, Kyle Kongpachith, Sarah Kline, Douglas E. Hendrickx, Wouter Cesano, Alessandra Butterfield, Lisa H. Kaufman, Howard L. Hudson, Thomas J. Bedognetti, Davide Marincola, Francesco Samayoa, Josue |
author_sort | Turan, Tolga |
collection | PubMed |
description | Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvironment: immune-active, immune-deserted and immune-excluded. This trichotomy is observable across most solid tumors (although the frequency of each landscape varies depending on tumor tissue of origin) and is associated with cancer prognosis and response to checkpoint inhibitor therapy (CIT). Various gene signatures (e.g. Immunological Constant of Rejection - ICR and Tumor Inflammation Signature - TIS) that delineate these landscapes have been described by different groups. In an effort to explain the mechanisms of cancer immune responsiveness or resistance to CIT, several models have been proposed that are loosely associated with the three landscapes. Here, we propose a strategy to integrate compelling data from various paradigms into a “Theory of Everything”. Founded upon this unified theory, we also propose the creation of a task force led by the Society for Immunotherapy of Cancer (SITC) aimed at systematically addressing salient questions relevant to cancer immune responsiveness and immune evasion. This multidisciplinary effort will encompass aspects of genetics, tumor cell biology, and immunology that are pertinent to the understanding of this multifaceted problem. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-018-0355-5) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5989400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-59894002018-06-20 Immune oncology, immune responsiveness and the theory of everything Turan, Tolga Kannan, Deepti Patel, Maulik Matthew Barnes, J. Tanlimco, Sonia G. Lu, Rongze Halliwill, Kyle Kongpachith, Sarah Kline, Douglas E. Hendrickx, Wouter Cesano, Alessandra Butterfield, Lisa H. Kaufman, Howard L. Hudson, Thomas J. Bedognetti, Davide Marincola, Francesco Samayoa, Josue J Immunother Cancer Hypothesis Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvironment: immune-active, immune-deserted and immune-excluded. This trichotomy is observable across most solid tumors (although the frequency of each landscape varies depending on tumor tissue of origin) and is associated with cancer prognosis and response to checkpoint inhibitor therapy (CIT). Various gene signatures (e.g. Immunological Constant of Rejection - ICR and Tumor Inflammation Signature - TIS) that delineate these landscapes have been described by different groups. In an effort to explain the mechanisms of cancer immune responsiveness or resistance to CIT, several models have been proposed that are loosely associated with the three landscapes. Here, we propose a strategy to integrate compelling data from various paradigms into a “Theory of Everything”. Founded upon this unified theory, we also propose the creation of a task force led by the Society for Immunotherapy of Cancer (SITC) aimed at systematically addressing salient questions relevant to cancer immune responsiveness and immune evasion. This multidisciplinary effort will encompass aspects of genetics, tumor cell biology, and immunology that are pertinent to the understanding of this multifaceted problem. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s40425-018-0355-5) contains supplementary material, which is available to authorized users. BioMed Central 2018-06-05 /pmc/articles/PMC5989400/ /pubmed/29871670 http://dx.doi.org/10.1186/s40425-018-0355-5 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Hypothesis Turan, Tolga Kannan, Deepti Patel, Maulik Matthew Barnes, J. Tanlimco, Sonia G. Lu, Rongze Halliwill, Kyle Kongpachith, Sarah Kline, Douglas E. Hendrickx, Wouter Cesano, Alessandra Butterfield, Lisa H. Kaufman, Howard L. Hudson, Thomas J. Bedognetti, Davide Marincola, Francesco Samayoa, Josue Immune oncology, immune responsiveness and the theory of everything |
title | Immune oncology, immune responsiveness and the theory of everything |
title_full | Immune oncology, immune responsiveness and the theory of everything |
title_fullStr | Immune oncology, immune responsiveness and the theory of everything |
title_full_unstemmed | Immune oncology, immune responsiveness and the theory of everything |
title_short | Immune oncology, immune responsiveness and the theory of everything |
title_sort | immune oncology, immune responsiveness and the theory of everything |
topic | Hypothesis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5989400/ https://www.ncbi.nlm.nih.gov/pubmed/29871670 http://dx.doi.org/10.1186/s40425-018-0355-5 |
work_keys_str_mv | AT turantolga immuneoncologyimmuneresponsivenessandthetheoryofeverything AT kannandeepti immuneoncologyimmuneresponsivenessandthetheoryofeverything AT patelmaulik immuneoncologyimmuneresponsivenessandthetheoryofeverything AT matthewbarnesj immuneoncologyimmuneresponsivenessandthetheoryofeverything AT tanlimcosoniag immuneoncologyimmuneresponsivenessandthetheoryofeverything AT lurongze immuneoncologyimmuneresponsivenessandthetheoryofeverything AT halliwillkyle immuneoncologyimmuneresponsivenessandthetheoryofeverything AT kongpachithsarah immuneoncologyimmuneresponsivenessandthetheoryofeverything AT klinedouglase immuneoncologyimmuneresponsivenessandthetheoryofeverything AT hendrickxwouter immuneoncologyimmuneresponsivenessandthetheoryofeverything AT cesanoalessandra immuneoncologyimmuneresponsivenessandthetheoryofeverything AT butterfieldlisah immuneoncologyimmuneresponsivenessandthetheoryofeverything AT kaufmanhowardl immuneoncologyimmuneresponsivenessandthetheoryofeverything AT hudsonthomasj immuneoncologyimmuneresponsivenessandthetheoryofeverything AT bedognettidavide immuneoncologyimmuneresponsivenessandthetheoryofeverything AT marincolafrancesco immuneoncologyimmuneresponsivenessandthetheoryofeverything AT samayoajosue immuneoncologyimmuneresponsivenessandthetheoryofeverything |